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Abstract | Glomerular filtration rate is inversely associated with cardiovascular disease 
independent of conventional risk factors. An increased risk of cardiovascular disease is 
present even at minor levels of renal impairment and the risk is highest in patients with end-
stage renal disease (ESRD) requiring dialysis. Renal dysfunction changes the level, 
composition, and quality of blood lipids in favour of a more atherogenic profile. Patients with 
advanced chronic kidney disease or ESRD have a characteristic lipid pattern of 
hypertriglyceridemia and low HDL-cholesterol levels but normal LDL-cholesterol levels. In 
the general population, a clear relationship exists between LDL-cholesterol, coronary heart 
disease and ischaemic stroke. However, in patients with ESRD, LDL-cholesterol seems to 
show a negative association [Au: with these outcomes?] at below average LDL-cholesterol 
levels and a flat or weakly positive association with mortality at higher LDL-cholesterol 
levels. Overall, the available data suggest that lowering of LDL-cholesterol is beneficial for 
prevention of major atherosclerotic events in patients with chronic kidney disease and in 
kidney transplant recipient but is not beneficial in patients requiring dialysis. [Au: I’ve 
moved the description of the content of your Review to the end of the introduction as 
per our journal style. To fully reflect the content of your article, please finish off the 
abstrace with a couple of sentences relating to novel lipid-lowering therapies and the 
need for reconsideration of the KDIGO guidelines in the light of new data. We have a 
limit of 200 words for this section.] 
 
[Au: I have highlighted suggestions for glossary terms throughout your manuscript 
with a [G]. Please provide succinct, one-sentence definitions for these specialist terms.]  
 
[H1] Introduction 
Guidelines regarding the management of lipids in patients with chronic kidney disease 
(CKD) and especially in those with end-stage renal disease (ESRD) are inconsistent in part 
owing to important deficiencies in the available data. [Au: Edit OK?] In 2013 KDIGO 
produced a comprehensive clinical practice guideline for lipid management in CKD1. [Au: I 
suggest that we cite your original Table 1 (now Table 3) in the discussion of KDIGO 
recommendations at the end of the review so that the table is included next to this 
discussion in the final layout rather than in the introduction to the Review.] However, in 
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contrast to other [Au: subsequently published?] guidelines [Au: Such as?], these 
recommendations are considered by some to be overly conservative and restrictive with 
respect to patient selection, repeat cholesterol measurements and escalation of lipid-lowering 
therapy, as well as to possibly encourage a nihilistic approach, particularly in patients who 
require dialysis2,3. 
 
To some extent these issues are related to the historical unavailability of low-cost, efficacious 
and well-tolerated non-statin-based lipid-lowering therapies. However, developments in the 
understanding of lipid metabolism, increasing evidence supporting the use of novel lipid-
lowering therapies, emerging clinical data and the publication of guidelines from learned 
societies mean that nephrologists and other health professionals may now have to reconsider 
their attitude towards the use of such therapies in patients with CKD and ESRD. 
 
Here we review the epidemiology, pathogenesis and treatment of dyslipidaemia in patients 
with CKD and ESRD and in kidney transplant recipients. We discuss the mechanisms of 
action of novel lipid-lowering agents, evaluate the emerging evidence that supports the use of 
these therapies and discuss the potential health economic implications of their adoption in 
clinical practice. [Au: Edit OK?] Finally, we reappraise the 2013 KDIGO Clinical Practice 
Guideline for Lipid Management in the context of the currently available data and more 
recent lipid management guidelines from other societies. [Au: Edit of this paragraph OK? 
I moved some text from the end of your abstract to provide more detail.] 
 
[H1] Renal function and cardiovascular risk [Au: We have a limit for main [H1] 
subheadings of 39 characters including spaces. I have edited the subheadings 
throughout to fit this limit.] 
A graded inverse relationship exists between estimated glomerular filtration rate (eGFR) and 
cardiovascular disease, which is independent of age, sex and other conventional 
cardiovascular risk factors4,5. This relationship is present even in the setting of minor renal 
impairment with most studies showing an increased risk [Au: of cardiovascular disease?] at 
an eGFR <60 ml/min/1.73m2 and some studies showing an increased number of 
cardiovascular events even at higher levels of eGFR4-6. Moreover, patients with ESRD who 
require dialysis have an extremely high risk of cardiovascular disease [Au: ok or should this 
be cardiovascular events?]7. In Europe, standardized cardiovascular and non-cardiovascular 
mortality are 8.1 and 8.8 times higher, respectively, in patients on dialysis than in the general 
population8. The mortality of patients with ESRD is twice as high as that of patients with 
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congestive heart failure and four times that of patients with diabetes mellitus in the absence 
of CKD7. In all relevant studies of patients with early CKD or ESRD published to date, 
cardiovascular disease is the predominant cause of this increased mortality, accounting for 
over 50% of all deaths4,5,7,9.  
 
Kidney transplantation is the treatment of choice for patients with ESRD and is associated 
with healthcare cost savings, improved quality of life and improved survival10-13. Candidates 
for kidney transplants undergo rigorous cardiovascular investigations before 
transplantation14. However, cardiovascular mortality still accounts for approximately 50% of 
all deaths in kidney transplant recipients15. 
 
[H1] Dyslipidaemia in kidney disease [Au: I have added [H2] subheadings to this section 
to make it easier to navigate for readers. Please check that you are happy with these 
headings. We have a limit for [H2] subheadings of 39 characters including spaces.]  
Patients with kidney disease are a very heterogenous population with a wide range of 
aetiologies of renal damage, levels of renal function and proteinuria, co-morbidities 
(especially concurrent diabetes), renal replacement modalities and treatments, all of which 
can affect the levels and properties of circulating lipids16,17. [Au: Edit OK?] In general, renal 
dysfunction changes the level, composition, and quality of these lipids in favour of a more 
atherogenic profile18-21. The characteristic lipid pattern in patients with CKD stage 3 or 
higher consists of hypertriglyceridemia [G] , low levels of high-density lipoprotein (HDL) 
cholesterol and variable levels of low-density lipoprotein (LDL) cholesterol and total 
cholesterol18,19,22-25. However, different CKD stages, modes of dialysis and levels of 
proteinuria are associated with specific lipid profiles (Table 1). [Au: Edit OK? We 
generally avoid referring directly to display items in the text.] 
 
[H2] Lipid metabolism 
Lipid metabolism is complex and involves multiple organs, cells and tissues, including the 
liver, intestine, plasma, macrophages and vascular endothelium, all of which can be affected 
by impaired kidney function19,26 (Figure 1). As fats are hydrophobic and generally insoluble 
in plasma26, they are transported within hydrophilic lipoproteins with surface apolipoproteins 
[Au: What is the function of apolipoproteins in this context?]. Hundreds of these proteins 
[Au: Are you referring to lipoproteins, apolipoprotiens or both?] exist26-28. 
Apolipoproteins also act as cofactors and ligands for lipid-processing enzymes.  
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Dyslipidaemia in patients with CKD occurs as a result of altered metabolism of postprandial 
lipoproteins and other triglyceride-rich lipoproteins (such as very low density lipoprotein 
(VLDL), intermediate density lipoprotein (IDL) and LDL), changes in reverse cholesterol 
transport and lipoprotein structure, post-translational modification of lipoproteins and 
increased levels of lipoprotein(a) (Lp(a)). [Au: Edit OK?]  
 
[H2] Lipoprotein structure 
LDL-cholesterol has been a major focus of cardiovascular risk reduction in patients with 
CKD16,18,19,22,24,29-32. However, the levels of LDL-cholesterol and total cholestrol are often 
within normal limits in these patients19,24,25,32-36. Alterations in lipoprotein structure that are 
associated with CKD, for example an increased predominance of atherogenic small dense 
LDL particles, might be more important than quantitative changes in cholesterol levels19,32-36. 
The increased pro-atherogenic potential of small dense LDL particles has been linked to their 
increased capacity to infiltrate the arterial intima and their increased susceptibility to 
oxidative modification [Au: compared with which LDL particles?]37-39.  
 
[H2] Reverse cholesterol transport 
The process of reverse cholesterol transport clears excess cholesterol from the arterial wall 
through HDL-cholesterol-mediated pathways (Figure 1)24,26. This process is negatively 
affected by CKD at several levels. Expression of the ATP-Binding Cassette (ABC) 
transporters, ABCA1 and ABCR1, which are key to promoting the efflux of cholesterol from 
macrophages to lipid-poor HDL precursors,24,40,41 is  reduced in CKD42. Activation of the 
plasma enzyme lecithin-cholesterol acyltransferase (LCAT) by Apolipoprotein-AI (Apo-AI; 
the major lipoprotein on HDL) to form cholesterol ester from free cholesterol stimulates the 
maturation of HDL precursors24,43. Levels of plasma Apo-A1 and HDL-cholesterol are also 
significantly reduced in patients with CKD as a consequence of reduced liver synthesis of 
Apo-A1 and reduced concentration and activity of LCAT24,43–45. 
 
Cholesterylester transfer protein (CETP) mediates the transfer of cholesterol ester from HDL 
particles to triglyceride-rich lipoproteins. Low CETP activity leads to increased plasma HDL-
cholesterol concentrations and is thought to protect against atheroma [G] formation although 
whether HDL cholesterol levels are a modifiable risk factor remains unclear24,46,47. However, 
CETP activity is increased in patients with CKD24,48,49. This impaired HDL-cholesterol 
metabolism in CKD leads to the accumulation of immature HDL particle precursors with 
limited anti-oxidative and anti-inflammatory potential 34,50-52. Renal transplant recipients 
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often have high levels of HDL-cholesterol but are not protected against atherogenesis, 
probably as a direct result of the reduced quality of these HDL particles13,53. 
 
[H2] Hypertriglyceridemia 
Plasma triglyceride concentrations are increased in the early stages of CKD with the highest 
levels in patients on dialysis and in those with nephrotic syndrome 34,54. The ratio of 
triglycerides to cholesterol in LDL and HDL particles is also increased in patients with 
CKD24. Hypertriglyceridemia [G] in CKD results from delayed catabolism of triglyceride 
rich lipoproteins, including VLDL particles and chylomicron [G] remnants, coupled to 
reduced LCAT activity34,43. Lipoprotein lipase (LPL) expression is reduced and the levels of 
Apolipoprotein C-III (Apo C-III), a competitive inhibitor of LPL, are increased in CKD24,55. 
LPL hydrolyses triglycerides transported within VLDL particles and chylomicrons56,57. 
Clearance of VLDL particles from the circulation, and their transformation into IDL 
particles, are also impaired in CKD because of reduced expression of VLDL receptors in 
adipocytes and myocytes 25,58-60. Glucose loading in patients on peritoneal dialysis61 and 
recurrent heparinisation in those on haemodialysis are also thought to contribute [Au: to this 
reduced expression?]62. Switching from conventional thrice-weekly 4-hour haemodialysis 
sessions to more intensive regimens such as nocturnal haemodialysis has been reported to 
lower triglyceride concentrations and increase HDL-cholesterol levels63. 
 
Attention has focused on alterations of triglyceride-rich lipoproteins as predictors of 
cardiovascular disease64. In the general population, Mendelian randomization analyses 
support the hypothesis of a causal association between triglyceride and lipoprotein 
abnormalities, including smaller and denser LDL and HDL particles and cardiovascular 
disease64,65. Patients with an eGFR <60 ml/min/1.73m2 have a highly-prevalent dyslipidemic 
phenotype consisting of increased levels of triglyceride-rich lipoproteins that is strongly 
associated with a high subclinical atherosclerosis burden66,67 and has also been shown to be 
associated with increased risk of coronary heart disease68. Hypertriglyceridaemia is also a 
strong [Au: risk?] factor for cardiovascular events and mortality in patients on haemodialysis 
with abdominal obesity69. 
 
[H2] Lipoprotein(a) 
Lp(a) is a unique lipoprotein that consists of a central LDL-like core containing a single 
molecule of Apoprotein-B (ApoB) linked by a disulphide bridge to Apoprotein(a) 31,70,71. 
Lp(a) binds to the extracellular matrix and is highly atherogenic31. Plasma Lp(a) levels are 
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primarily genetically determined by Lp(a) gene variants and are thought to be causally 
associated with high cardiovascular risk based on epidemiologic, genetic association and 
Mendelian randomization studies31,70,72-76. Interestingly this association seems to become less 
important once coronary artery disease is established77. Elevated Lp(a) levels are also 
independently associated with risk of myocardial infarction and death in patients with CKD78.  
 
The metabolic pathways of Lp(a) production and clearance are not well understood70. 
However, plasma Lp(a) levels seem to increase early in CKD owing to decreased clearance79 
and are increased up to 4-fold in patients with nephrotic syndrome 80,81. Lp(a) is thought to 
competitively inhibit fibrinolysis [G] and thus predispose to thrombosis and may also directly 
promote atherosclerosis70. The 2016 ESC/EAS Guidelines for the Management of 
Dyslipidaemias recommend measuring of ApoB as an complementary risk marker, especially 
in patients with high triglyceride levels, and measuring of Lp(a) levels in selected patients at 
high risk of cardiovascular disease, in patients with premature cardiovascular disease, and for 
reclassification in patients with borderline cardiovascular risk79. 
 
[H2] Oxidative stress 
Oxidative stress increases as renal function declines82, leading to increased oxidation of 
circulating lipids19. The resulting oxidation products such as oxysterols83,84, malondialdehyde 
85,86, and oxidized HDL and LDL particles87,88 have increased atherogenic potential. Studies 
of the lipidomic profile in the CKD population show a reduction in phosphatidylcholines, 
sulfatides and ceramides in LDL particles, as well as an increase in N-acyltaurines 89. These 
alterations may contribute to the pro-atherogenic potential of lipoproteins in CKD. Other 
qualitative abnormalities such as glycosylation and carbamylation have been reported in 
patients with CKD90. HDL particles in adult and paediatric patients with CKD are modified 
by retained symmetric dimethylarginine promoting endothelial dysfunction and 
atherogenesis91. 
 
[H2] Nephrotic syndrome 
Independent of alterations in GFR, increasing levels of albuminuria are associated with 
dysregulation of lipid metabolism and dyslipidaemia,which is exemplified in patients with 
nephrotic syndrome80,81,92. These patients typically have marked hypercholesterolaemia, 
hypertriglyceridaemia and low to normal HDL-cholesterol levels. These changes are 
mediated by changes in the expression and activity of key protein mediators of lipid 
metabolism, including decreased LPL activity and decreased expression of the LDL-receptor 
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(LDL-R) 80,81,92, which in part relate to the insulin resistant state that is observed in these 
patients. Profound alterations in the structure and function of HDL particles are also present 
[Au: in patients with nephrotic syndrome?]81. Increases in proprotein convertase 
subtilisin–kexin type 9 (PCSK9) are also thought to contribute to the hypercholesterolaemia 
that is associated with nephrotic syndrome80,93. Plasma PCSK9 concentrations do not increase 
with decreasing GFR [Au: Please explain why this finding is important.]94. 
 
[H2] Immunosuppressive medication 
Kidney transplant recipients and patients with autoimmune or inflammatory conditions, which 
can be a cause of renal damage or an associated comorbidity, require treatment with 
immunosuppressive medication, which substantially alter lipid profiles95. Calcineurin 
inhibitors, particularly ciclosporin, increase LDL-cholesterol levels by a number of 
mechanisms, including reduced binding to the LDL-R, decreased bile acid synthesis and the 
promotion of glucose intolerance96,97. Although ciclosporin and tacrolimus seem to have 
similar actions on lipid metabolism and glucose intolerance, the use of ciclosporin is 
consistently associated with increased levels of LDL-cholesterol and Apo(B)98-100. mTOR 
inhibitors have anti-atherogenic effects but raise LDL-cholesterol levels at least as much as or 
even more than calcineurin inhibitors by a number of potential mechanisms including 
inhibition of LPL and increased lipoprotein synthesis [Au: Edit OK?]95,101-103. In addition, 
corticosteroids induce insulin resistance and dose-dependently increase concentrations of 
circulating cholesterol and triglycerides95. The effects of these drugs on dyslipidemia is 
additive to that of other immune-suppressive agents. 
 
[H1] Lipids and cardiovascular disease 
In the general population, a clear linear relationship exists between plasma cholesterol 
concentration and the risk of coronary heart disease and ischaemic stroke. For every 1 mmol/L 
(40 mg/dL) increase in LDL-cholesterol, the risk of coronary heart disease increases by 40%104. 
However, in patients with ESRD on dialysis, LDL-cholesterol has a negative association with 
all-cause mortality at below average LDL-cholesterol levels and a flat or weakly positive 
association at higher levels105,106. [Au: Edit OK?] This relationship, which holds for patients 
on haemodialysis or peritoneal dialysis and when cardiovascular death is considered as a 
separate outcome106, is often referred to as “reverse epidemiology”, “reverse causality” or “the 
risk factor paradox”. That is, CKD or an associated co-morbidity causes both reduced LDL-
cholesterol levels and an increased risk of death, thus creating a potentially deceptive 
association between low LDL-cholesterol levels and mortality107,108. However, an analysis of 
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the Study of Heart and Renal Protection (SHARP) found a weak linear relationship between 
LDL-cholesterol and the risk of major vascular events (HR 1.14, 95% CI 1.06-1.22 per 0.6 
mmol/L increase in LDL-cholesterol) in 9,270 patients with moderate to advanced CKD, 
including 3,015 patients on dialysis109. [Au: Please clarify how this finding supports or does 
not support the reverse causality hypothesis as this is not currently clear.]  
 
Another possible or complimentary explanation [Au: “for the inverse relationship between 
LDL-cholesterol levels and all-cause mortality in patients with ESRD”?] is that CKD 
results in a unique cardiovascular phenotype with fewer deaths due to atherosclerotic processes 
but more deaths owing to heart failure and sudden cardiac death110-112. The pathophysiology of 
these conditions seems to be associated with disturbances of calcium and phosphate 
metabolism, hypertension, arrhythmogenic electrolyte disorders, hypervolaemia, uraemic 
toxins and anaemia113-115. A specific pattern of myocardial fibrosis that is found in patients 
with CKD and ESRD known as cardiomyopathy of CKD or uraemic cardiomyopathy is 
thought to form the pathophysiological basis for this phenotype, which is a powerful predictor 
of cardiovascular mortality in these patients115-117.  
 
Increased HDL-cholesterol levels are associated with decreased cardiovascular risk in the 
general population118-120. However, RCTs in this population have not shown significant 
benefits of increasing HDL-cholesterol levels with non-statin medications, including 
niacin121-124. Low levels of HDL-cholesterol are common among patients with CKD and 
ESRD125-127 but they do not seem to be associated with increased cardiovascular risk after 
adjustment for traditional risk factors128,129. Some studies show a J-curve association with 
increased mortality among patients with ESRD who have very low or very high HDL-
cholesterol levels130-132. These data further support the importance of renal-function-induced 
changes in the composition and quality of lipoproteins. 
 
In the general population, hypertriglyceridaemia is an independent cardiovascular risk factor 
although the association is far weaker than for hypercholesterolaemia133. Elevated 
triglyceride levels are common in patients with CKD and ESRD, especially in those with 
insulin resistance and diabetes mellitus, and in those who are receiving peritoneal dialysis134-
137. 
 
[H1] Statin therapy 
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Beneficial effects of lowering LDL-cholesterol levels using HMG-CoA (3-hydroxy-3-
methylglutaryl-coenzyme) reductase inhibitors, commonly known as statins, are well 
established in patients without renal dysfunction. Their safety and efficacy has been 
demonstrated in the setting of secondary prevention following an atherosclerotic 
cardiovascular event in several adequately powered RCTs138,139, and as primary prevention in 
patients at increased cardiovascular risk such as those with diabetes140,141.  
 
The overwhelming nature and magnitude of benefit of statin therapy in high-risk populations 
has also been demonstrated in a number of meta-analyses from the Cholesterol Treatment 
Trialists (CTT) collaboration 142-145. Statins might also be beneficial as primary therapy to 
prevent cardiovascular disease in lower risk populations145 such as in men with 
hypercholesterolaemia146 or in men and women with high levels of high-sensitivity C-
Reactive protein (hsCRP; a marker of inflammation) in the absence of hyperlipidaemia 147. 
To date, all of the large randomized controlled studies (RCTs) that have investigated the 
efficacy of lipid-lowering therapy for the prevention of cardiovascular events in patients with 
kidney disease have been performed using statins. 
 
[H2] Randomized controlled trials 
Many of the early RCTs of statin therapy [Au: of statin therapy?] did not focus on renal 
dysfunction as a cardiovascular risk factor. However, the Pravastatin Pooling Project, which 
combined the results of three placebo-controlled pravastatin trials, demonstrated that reduced 
kidney function (eGFR 30-59 ml/min/1.73m2) was a predictor of cardiovascular events and 
that lipid lowering was associated with a reduction in the rate of these events in patients with 
reduced kidney function [Au: Edit OK?]148. Similar results were seen in patients with reduced 
kidney function (defined as eGFR <60 ml/min/1.73m2) in the JUPITER149 and Treating to New 
Targets (TNT) trials150.  
 
[H3] Kidney transplant recipients. The first large RCT of statin therapy for the prevention 
of cardiovascular events in kidney transplant recipient was the Assessment of Lescol in Renal 
Transplantation (ALERT) study, which included 2,102 kidney transplant recipients receiving 
ciclosporin-based immunosuppression with stable graft function and total cholesterol levels of 
4.0-9.0 mmol/L (155–350 mg/dL) or 4.0-7.0 mmol/L (155–270 mg/dL) if they had previously 
experienced a myocardial infarction151. Patients were randomly assigned to 40 mg fluvastatin 
or placebo and followed for a mean of 5.1 years. LDL-cholesterol was 1.0 mmol/L (40 mg/dL) 
lower in the statin group than in the placebo group following the intervention [Au: at what 
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follow-up?]. Although intervention with fluvastatin failed to reduce the incidence of the 
combined primary end point of major cardiac events (defined as cardiac death, non-fatal 
myocardial infarction or coronary intervention), this lipid-lowering therapy was associated 
with a significant reduction in non-fatal myocardial infarction and cardiac deaths151. However, 
the fairly low number of patients and the lack of a run-in period limited the power of ALERT 
to detect a difference in outcomes over this time period.  
 
In a complex extension study, all of the ALERT participants were offered open-label, longer-
term high dose (80 mg) fluvastatin and followed for a total of 6.7 years152. During this period, 
the benefits of random assignment to the fluvastatin group in the initial study in terms of non-
fatal myocardial infarction and cardiac death were sustained [Au: Edit OK?]. Therefore, the 
overall conclusion was that statins seem to be safe and efficacious at reducing atherosclerotic 
cardiovascular events in renal transplant recipients. Some discrepancies were observed in the 
magnitude of benefit in kidney transplant recipients compared to non-ESRD populations [Au: 
in which studies?], mainly driven by lack of effect on coronary artery revascularization. [Au: 
Please provide a bit more detail on these discrepancies. Was the magnitude of benefit in 
transplant recipients not as great as in the general population?] 
 
[H3] Patients with CKD or ESRD. Two large RCTs in patients on dialysis, the Die Deutsche 
Diabetes Dialyse Studie (4D)154 and A Study to Evaluate the Use of Rosuvastatin [Au: 
Changed from atorvastatin. OK?] in Subjects on Regular Haemodialysis: An Assessment of 
Survival and Cardiovascular Events (AURORA)153, showed no benefit of statin therapy in 
patients with ESRD. In the 4D study, 1,255 patients with diabetes who had been on 
haemodialysis for <2 years (of whom 29% had prior cardiovascular disease) were randomly 
assigned to atorvastatin 20 mg or placebo, with those on a statin undergoing a washout period 
with placebo for 4 weeks154. In the intervention group, LDL-cholesterol levels were reduced 
from median of 3.13 mmol/L (121 mg/dL) by a mean of 1.27 mmol/L (49 mg/dL) [Au: at 
what time point?]. Despite this reduction, no significant reduction was observed in the 
incidence of the combined outcome of major cardiovascular events ([Au: death from cardiac 
causes, nonfatal myocardial infarction, and stroke?]) with atorvastatin compared with 
placebo over a median of 4 years of follow up (HR 0.92, 95% CI 0.77-1.10). However, 
atorvastatin therapy did reduce the rate of all cardiac events combined compared with placebo 
(RR 0.82 95% CI 0.68-0.99).  
 
 12 
In AURORA, 2,776 patients who had been treated with haemodialysis for at least 3 months 
and were not receiving statin therapy were randomly assigned to rosuvastatin 10 mg daily or 
placebo153. Nearly 40% of patients enrolled in AURORA had known cardiovascular disease of 
whom 10% [Au:OK?] had a prior myocardial infarction. The fact that these patients were not 
on statins at recruitment might illustrate the undertreatment of patients [Au: “with ESRD”?] 
even for secondary prevention [Au: “of cardiovascular disease”?]. In contrast to the 4D study, 
74% of the AURORA participants were diabetic; however only patients over the age of 50 
years were recruited whereas the 4D participants were aged over 18 years. Although LDL-
cholesterol levels [Au: “in the rosuvastatin group”?] fell by 43% from a mean baseline of 
2.6 mmol/L (100 mg/dL), and this reduction was accompanied by a significant decrease in C-
reactive protein levels, no significant reduction was observed in the incidence of major cardiac 
events with rosuvastatin compared to placebo after a median follow up of 3.8 years (HR 0.96 
95% CI 0.84-1.11). However, the combined primary end point in AURORA was not specific 
and included non-atherosclerotic events. 
 
Importantly, patients were not selected on the basis of hypercholesterolaemia in any of these 
studies [Au: Are you referring to ALERT, 4D and AURORA or just 4D and AURORA 
here?]. Although patients with an LDL-cholesterol level >4.9 mmol/L (190 mg/dL) were 
excluded from the 4D trial154, atorvastatin therapy significantly reduced the risk of fatal and 
non-fatal cardiac events in participants with a pre-treatment LDL-cholesterol level >3.76 
mmol/L (>145 mg/dl)155. However, this type of subanalysis should be interpreted with caution. 
[Au: Why?] 
 
The double-blind, randomized Study of Heart and Renal Protection (SHARP) tested the effect 
of lipid lowering with simvastatin plus ezetimibe for primary prevention of atherosclerotic 
vascular events in 9,270 patients with CKD156. At enrollment, 6,247 of these patients did not 
require dialysis and had a serum creatinine level greater than 150 μmol/L (1.7 mg/dL) for men 
or greater than 130 μmol/L (1.5 mg/dL) for women; the remaining 3,023 patients were on 
dialysis156. Of note, about 30% of the study population had stage 4 CKD and 13% were already 
at Stage 5 CKD but not on dialysis; thus, 75% of the study population had CKD Stage 4 or 5.  
 
On enrolment, the SHARP participants were initially randomly assigned to simvastatin plus 
ezetimibe, simvastatin alone and placebo groups. After 1 year, those who were initially 
allocated to simvastatin alone were randomly re-assigned to receive either simvastatin plus 
ezetimibe or placebo. Lipid lowering with simvastatin 20 mg combined with ezetimibe 10 mg 
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led to a mean difference in LDL-cholesterol levels of 0·85 mmol/L (33 mg/dL) compared to 
placebo. After an average of 4.9 years of follow up, a significant reduction (HR 0.83 95% CI 
0.74-0.94) was observed in major atherosclerotic events [Au: in the simvastatin plus 
ezetimibe group?].  
 
The cardiovascular events in SHARP were more tightly defined than in 4D or AURORA, 
specifically focusing on thrombo-occlusive disease that would be modifiable with lipid-
lowering therapy. Thus the primary outcome was a composite of major atherosclerotic events 
(coronary death, myocardial infarction, non-haemorrhagic stroke or any revascularization). 
The effect of treatment [Au: do you mean lipid lowering?] was not associated with a 
significant reduction in these events when only patients who were already on dialysis at 
enrolment were considered (HR 0.90 95% CI 0.75-1.08). However, SHARP was not powered 
to detect a benefit in this patient group. After weighting for subgroup-specific reductions in 
LDL-cholesterol levels, the effects on outcomes in patients on dialysis did not differ from those 
in patients with non-dialysed CKD (χ2=1.34; P=0.25). The SHARP study clearly demonstrates 
a benefit of lowering LDL-cholesterol levels in patients with CKD not requiring dialysis, which 
is in keeping with the association of these levels with cardiovascular disease in this 
population109,157. Notably, a post hoc analysis of the SHARP data showed that lowering of 
LDL-cholesterol was not associated with any delay in progression of CKD158. This finding is 
in line with the results of a subsequent meta-analysis159. 
 
Despite the differences [Au: in study populations, interventions and outcomes?] between 
the 4D, AURORA and SHARP studies, the apparent lack of efficacy of statins for prevention 
of cardiovascular events in patients on dialysis was remarkably similar. Several potential 
explanations for this failure exist. First, LDL-cholesterol is not associated with cardiovascular 
disease in patients on dialysis. However, such a lack of association seems unlikely given the 
well-established direct causal relationship between LDL-cholesterol and atheroma143,145. 
Second, cardiovascular events in patients on dialysis are proportionally increased due to non-
atheromatous processes such as sudden death and heart failure, which would not necessarily 
be directly improved by lowering of LDL-cholesterol levels110,111. Third, all three studies had 
relatively small numbers of patients on dialysis compared with other studies of lipid lowering 
therapies (for example the Scandinavian Simvastatin Survival Study (n = 4,444)138 and the 
West of Scotland Coronary Prevention Study (n = 6,595)146) and could therefore have been 
underpowered to detect a modest effect. 
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[H3] Adverse effects. [Au: I’ve moved this discussion from the health economics section 
as I think it is more logical to include it in the discussin of statin therapy. OK?] In the 
very large RCTs conducted to date, the only serious adverse events that have been reported 
with long-term statin treatment are myopathy (defined as muscle pain and/or weakness in 
conjunction with significantly raised serum creatine kinase levels), new onset diabetes 
mellitus and possibly haemorrhagic stroke [Au: Please reference this statement.]. Treating 
10,000 patients for 5 years with an effective statin (for example atorvastatin 40 mg) would 
cause five cases of myopathy, with one case progressing to full-blown rhabdomyolysis if the 
statin was not discontinued, 50-100 cases of muscle pain and weakness that do not meet the 
criteria for myopathy, 50-100 cases of diabetes mellitus and 5-10 haemorrhagic strokes. [Au: 
Please reference this statement.] The findings of large placebo-controlled RCTs suggest 
that most of these adverse effects are not directly attributable to the statin treatment144. 
However, controversy persists regarding how well data on adverse effects have been 
collected in these RCTs260.  
 
[H2] Meta-analyses 
Meta-analyses have shown that the proportional reduction in LDL-cholesterol levels achieved 
during statin trials in the general population is directly associated with the proportional 
reduction in risk of major vascular events142. In these studies, a 1 mmol/L reduction in LDL-
cholesterol is associated with a 22-23% reduction in these events142. Although observational 
data have important limitations, especially in regards to confounding and bias144, this reduction 
is approximately half that predicted from the observational relationship (40% would be 
expected)104. This finding is perhaps not particularly surprising. In most of the [Au: statin?] 
trials patients were treated for around 5 years whereas exposure to LDL-cholesterol in 
epidemiological studies lasts a lifetime. However, the relationship seems to be modified in 
patients with CKD suggesting that the worse the renal function, the lower the cardiovascular 
risk reduction per reduction in LDL-cholesterol levels112,160 with no risk reduction being 
demonstrable in patients on dialysis112. In general, statins tend to increase circulating levels of 
Lp(a) and these may contribute to residual cardiovascular risk [Au: despite lowering of LDL 
cholesterol levels?]161. As discussed above, circulating concentrations of Lp(a) increase with 
declining renal function and are highest in patients on dialysis162. Whether this finding explains 
the reduced cardiovascular benefit of LDL-lowering in patients with CKD compared with the 
general population remains to be determined162. [Au: Edit OK? Is this what you meant?]  
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A number of meta-analyses have pooled data from trials in patients with varying degrees of 
CKD and ESRD to study the effect of lipid lowering with statins and/or lowering of LDL-
cholesterol using ezetimibe in these populations [Au: Refs 164-169?]. The consistent finding 
of the individual trials is that lowering of LDL-cholesterol is beneficial for prevention of major 
atherosclerotic events in patients not requiring dialysis (including kidney transplant recipients), 
whereas lipid lowering has no obvious benefit in patients on dialysis. [Au: Edit OK?] 
However, the findings of the meta-analyses are somewhat conflicting164-169. [Au:OK?]  
 
The most comprehensive of these meta-analyses, which was conducted by the CTT 
collaboration, analysed data from 28 trials of statin-based therapy in patients with various 
degrees of renal impairment and included readjudication of all deaths in the AURORA trial to 
align with atherosclerotic end-points in the trials conducted in patients on dialysis112. This 
meta-analysis demonstrated that as eGFR declines there is a trend towards smaller relative risk 
reductions for major coronary events and strokes with stain therapy, even after adjusting for 
smaller reductions in LDL-cholesterol levels in patients with more severe CKD. In particular, 
there was little evidence that statin-based therapy reduced cardiovascular events in patients 
who were already on dialysis112. However, despite the reduced relative risk benefit of statin-
based cholesterol lowering in ESRD, an absolute benefit may persist as the total number of 
atherosclerotic events in this population is extremely high, especially in high-risk patients such 
as those with concomitant diabetes mellitus3,112. Indeed, a sub-analysis of the 4D study showed 
that atorvastatin treatment significantly lowered the risk of fatal and nonfatal cardiac events in 
patients with type 2 diabetes on haemodialysis with pre-treatment LDL-cholesterol levels 
>3.76 mmol/L (>145 mg/dL)155. However, as always, the results of secondary analyses should 
be interpreted with caution. 
 
[H2] Anti-inflammatory effects 
Inflammation has been implicated in the pathophysiology of cardiovascular disease in the 
general population and in patients with CKD [Au: or ESRD?]170,171. A chronic inflammatory 
state is observed in these patients owing to factors including decreased clearance of pro-
inflammatory cytokines, increased oxidative stress, acidosis, infections and the dialysis 
procedure177-180. Therefore, targeting inflammation, either directly or indirectly might 
improve outcomes independently of lipid-lowering in patients with CKD or ESRD. [Au: I 
suggest that you cut the discussion of the CANTOS study as it does not fit the scope of 
lipid-lowering therapies in CKD/ESRD or the subheading of anti-inflammatory effects 
of statins.] 
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Several lines of evidence support an anti-inflammatory action of statins [Au:OK?]172. 
Moreover, the JUPITER trial showed that potent statin therapy reduced the risk of major 
cardiovascular events by 44% in patients with elevated levels of hsCRP173. Intriguingly, this 
reduction in cardiovascular risk was associated with the [Au: reduction in?] level of hsCRP 
but not with that of LDL-cholesterol. [Au: Please can you check if this is correct. The 
abstract says that a reduction in LDL cholesterol to less than 1.8 mmol was associated 
with a 55% reduction in vascular events.] Similar reductions in cardiovascular risk were 
found in a secondary analysis of the 3,267 JUPITER participants who had an eGFR <60 
ml/min/1.73m2.149 However, in this subgroup similar reductions were observed in the levels 
of hsCRP and LDL-cholesterol. [Au: Please clarify the point that you are making here. 
Do you mean that statin therapy resulted in similar reductions in hsCRP and LDL-C or 
that reductions in hsCRP and LDL-C were similarly associated with reducions in 
cardiovascular events?] Of note, patients with a creatinine level greater than 177 μmol/L 
(greater than 2 mg/dL) were excluded from the JUPITER trial.  
 
A sub-analysis of the SHARP trial showed that although higher baseline hsCRP levels were 
associated with an increased risk of major cardiovascular events, the reduction in 
cardiovascular risk in those who received combination therapy with simvastatin and 
ezetimibe was similar irrespective of baseline hsCRP109. [Au: Edit OK?] Although the 
results of subanalyses should be interpreted with caution, this finding suggests that the 
simvastatin and ezetimibe combination reduces cardiovascular risk independently of the 
presence of inflammation.  
 
[H1] Fibrates 
RCTs have shown that lowering triglyceride levels with fibrate monotherapy decreases 
cardiovascular risk in the general population, although this benefit may be limited to 
individuals with very high triglyceride and very low HDL-cholesterol levels181-184. However, 
the use of fibrates, although possibly not gemfibrozil185, to lower triglyceride levels may 
increase creatinine levels, especially in patients with eGFR <30 ml/min/1.73m2 184,186,187, by 
mechanisms that are not fully elucidated184,188,189. Currently very little evidence exists to 
recommend the use of fibrates in patients with CKD unless triglyceride levels are very high 
(>1,000 mg/dL; 11.3 mmol/L) in which case these therapies should be used judiciously and 
dose adjusted for renal function1.  
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[H1] Bile acid sequesterants 
[Au: What is the rationale for using bile acid sequeserants or omega-3 oil in patients 
wih CV disease or CKD? What is their effect on lipids?] Although bile acid sequestrants 
(cholestyramine, colestipol, colesevelam) are currently recommended as second-line options 
in patients with atherosclerotic cardiovascular disease 79,190 a 2018 meta-analysis failed to 
identify any RCTs [Au: showing a benefit of these agents?] with more than 500 patients 
and greater than 1 year follow-up 191. Currently very little evidence exists to support the use 
of bile acid sequestrants or prescription omega-3 oil in patients with CKD or ESRD. 
 
[H1] Emerging lipid-lowering therapies 
Treatment of dyslipidaemia with the most widely used lipid-lowering drugs provides a 
significant reduction in cardiovascular risk. However, a significant proportion of [Au: 
treated?] patients will continue to have cardiovascular events31,192. Several novel therapies 
for the treatment of dyslipidaemias and their associated risks are being developed. These 
therapies include agents that target major mediators of the clearance and secretion of 
atherogenic proteins (Table 2). [Au: ATP citrate lyase inhibitors, acetylcoenzyme A 
carboxylase inhibitors and diacylglycerol acyltransferase 1 inhibitors are 
included in table 2 but do not seem to be discussed in the main text. For 
completeness, please also discuss these agents if appropriate.] 
 
[H2] PCSK9 inhibitors 
[Au: I’ve rearranged text in this paragraph to improve flow.] Proprotein convertase 
subtilisin–kexin type 9 (PCSK9) is a secreted serine protease that binds to the extracellular 
domain of the hepatocyte LDL-receptor and promotes its lysosomal degradation. This 
receptor degradation reduces LDL particle uptake and leads to increased concentrations of 
[Au: circulating?] LDL-cholesterol (Figure 2)199,200. In 2003, gain-of-function mutations in 
the gene encoding PCSK9193 were reported to cause autosomal dominant 
hypercholesterolemia194. Subsequently, loss-of-function mutations in PCSK9 were 
discovered to reduce LDL-cholesterol levels by 15-28% and the risk of coronary heart 
disease by 47–88%195-198. 
 
Monoclonal antibodies that act as PCSK9 inhibitors sequester PCSK9 and thereby prevent 
LDL-receptor catabolism so lead to an increase in LDL-receptor density on hepatocytes17,201. 
The efficacy of one such antibody, alirocumab, has been investigated in the Effect of 
Alirocumab on the Occurrence of Cardiovascular Events in Patients Who Have Recently 
 18 
Experienced an Acute Coronary Syndrome (ODYSSEY) clinical trial program, which 
includes approximately 23,500 patients worldwide. [Au: Please reference this statement.] 
Overall, these trials showed that alirocumab therapy reduced LDL-cholesterol levels by 36%-
61% after a minimum of 24 weeks of treatment [Au: Please reference the original paper 
from the ODYSSEY program in which this data was published.]. Alirocumab also 
consistently reduced concentrations of total cholesterol, ApoB, non-HDL-cholesterol, and 
Lp(a) independently of statin treatment and of additional ezetimibe use in heterozygous 
familial hypercholesterolaemia (HeFH) and non-FH populations202. A post hoc analysis of 
the Long-term Safety and Tolerability of Alirocumab in High Cardiovascular Risk Patients 
with Hypercholesterolemia Not Adequately Controlled with Their Lipid Modifying Therapy 
(ODYSSEY LONG TERM) study showed a 52% reduction in major cardiovascular events 
after alirocumab treatment in patients with HeFH and high cardiovascular risk already on the 
highest tolerated dose of statins 204. 
 
An analysis that pooled data from 8 phase 3 ODYSSEY trials of double-blind treatment with 
alirocumab for 24-104 weeks included 4,629 patients with hypercholesterolaemia of whom 
467 had CKD stage 3203. Among the patients with CKD, 315 were randomly assigned to 
alirocumab and 99% were already receiving a statin. The reduction in LDL-cholesterol levels 
at week 24 in patients with CKD treated with alirocumab ranged from 46.1% to 62.2% with 
an efficacy and safety profile comparable to that of patients with normal renal function 
(eGFR >60 ml/min/1.73m2). 
 
The ODYSSEY OUTCOMES trial included 18,924 participants who had experienced an 
acute coronary event 1-12 months before enrolment205. Following a run-in phase of 2-16 
weeks on high intensity statin therapy, these participants were randomly assigned to 
fortnightly alicorumab treatment or placebo groups. The alicorumab therapy was titrated to 
keep LDL-cholesterol levels between 0.65 mmol/l and 1.3 mmol/L (25-50 mg/dL). In this 
trial, alicorumab therapy resulted in a significant reduction in the primary outcome of major 
cardiac events (HR 0.85; 95% CI 0.78-0.93; P=0.0003) 205. [Au: Were patients with CKD 
included in this trial? If so is here any data on outcomes in this population?]  
 
The efficacy of another PCSK9 inhibitor, evolocumab, is being assessed in the Program to 
Reduce LDL-cholesterol and Cardiovascular Outcomes Following Inhibition of PCSK9 in 
Different Populations (PROFICIO)206-210. This program of 14 phase III clinical trials aims to 
recruit approximately 30,000 patients. So far, studies have ranged from from 10 to 52 weeks 
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in duration and have included patients treated either with evolocumab monotherapy or with 
evolocumab in combination with a statin or ezetimibe [Au: Is in combination with 
correct?]. Very significant reductions in LDL-cholesterol levels have been reported, ranging 
from 49%-65% ,with substantial reductions in the levels of non-HDL-cholesterol, ApoB and 
Lp(a) and modest effects on triglycerides and HDL-cholesterol. In addition, coronary 
atheroma regression with evolocumab compared with placebo (-0.95% versus +0.05%) has 
been reported in a double-blind, placebo-controlled trial in 968 patients with proven coronary 
atheroma on angiography that used serial intravascular ultrasound to assess atheroma 
volume211. A greater proportion of patients in the evolocumab group than in the placebo 
group also had plaque regression in this trial (64.3% versus 47.3%)211. 
 
The Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with 
Elevated Risk (FOURIER) trial, included 27,550 patients with known atherosclerotic 
vascular disease (previous myocardial infarction, non-haemorrhagic stroke or symptomatic 
peripheral vascular disease), LDL-cholesterol greater than 1.8 mmol/L (>70 mg/dL) or non-
HDL-cholesterol greater than 2.6 mmol/L (>100 mg/dL) already on optimized statin therapy 
212. This study reported a significant reduction in the primary outcome (composite of 
cardiovascular death, myocardial infarction, stroke, hospital admission for unstable angina or 
coronary revascularization) with evolocumab therapy (9.8%) compared with placebo (11.3%) 
(HR 0.85 95% CI 0.79-0.92) 212. Although patients with an eGFR >20 ml/min/1.73m2 were 
eligible for inclusion in FOURIER213, no information on the number and of patients with 
CKD who were enrolled and the outcomes in this population is currently available. 
 
The safety and efficacy of another monoclonal antibody, bococizumab, in patients at high 
cardiovascular risk was investigated in the Studies of PCSK9 Inhibition and the Reduction of 
Vascular Events (SPIRE) 1 and SPIRE 2214. [Au: What were the findings of these studies?] 
However, further clinical development of this agent has been stopped because of an 
unexpected decrease in LDL-cholesterol lowering over time, high levels of immunogenicity 
and high rates of injection-site reactions31. 
Unlike therapeutic antibodies which bind to and inhibit their target protein, treatment with 
short interfering RNAs (siRNAs) results in the destruction of the target messenger RNA and 
reduces the production of the protein215. Inclisiran (ALN-PCSSC) is a fully chemically 
modified, siRNA conjugated to triantennary N-acetylgalactosamine that inhibits the synthesis 
of PCSK9 216. In a phase 1 trial in healthy volunteers with a LDL-cholesterol level >2.59 
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mmol/L (100 mg/dL), a single dose of inclisiran >100 mg lowered LDL-cholesterol levels by 
a mean of 50.6% from baseline with reductions maintained for up to 6 months in those who 
received doses >300 mg 217.  
In a phase 2 multicentre study (ORION-1), 501 patients at high cardiovascular risk with 
elevated LDL-cholesterol levels received 2 doses of inclisiran (300 mg) at 0 and 90 days218. 
This regimen reduced LDL-cholesterol levels by 52.6 % with 48% of patients having an 
LDL-cholesterol concentration <0.04 mmol/L (1.5 mg/dL) at 180 days. Sustained reductions 
in apoB, non-HDL-cholesterol, VLDL-cholesterol and triglyceride levels as well as modest 
increases in HDL-cholesterol and apoA1 were also reported 219. The magnitude of these 
changes are broadly comparable to those observed in trials of PCSK9-inhibiting monoclonal 
antibodies219. Although preliminary, these results raise the possibility of lowering cholesterol 
levels using twice yearly injections. This possibility is now being investigated in an extension 
study of ORION-1, which involves a head-to-head comparison between inclisiran 300 mg 
every 180 days and fortnightly evolucamab (ORION-3; NCT03060577). [Au: Please add his 
study to the reference list.] 
[Au: Please add the trials mentioned in this paragraph to the reference list.] Ongoing 
trials are investigating the safety and efficacy of inclisiran in patients with familial 
hypercholesterolaemia (ORION-2; NCT02963311) and in patients with atherosclerotic 
cardiovascular disease (ORION-4). In addition, an open-label single dose study of 300 mg 
inclisiran is planned in 24 patients with renal impairment with a creatine clearance as low as 
15 ml/min (ORION-7; NCT0315946). 
 
[H2] CETP inhibitors 
Cholesteryl ester transfer protein (CETP) mediates the exchange of cholesteryl esters and 
triglycerides between mature HDLs and triglyceride-rich ApoB-containing lipoproteins and 
LDLs, thus modifying the lipid composition of HDLs (Figure 3)31. The first CETP inhibitor 
tested in humans, torcetrapib121,220, increased HDL-cholesterol levels by 72% and decreased 
LDL-cholesterol levels by 25%. However, this [Au: Please clarify what “this” refers to.] was 
associated with an increased risk of cardiovascular events and mortality, probably through 
CETP-independent actions on blood pressure and circulating aldosterone and endothelin-1 
levels121,221.  
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The development of the CETP inhibitors evacetrapib and dalcetrapib was halted because of a 
lack of beneficial effects on cardiovascular events, despite improvement of the lipid profile 
(more than doubling of HDL-cholesterol level and 30% decrease in LDL-cholesterol level) 
[Au: in which patient group?] 31,123,222,223. Another CETP inhibitor anacetrapib increased 
HDL-cholesterol by 138% and reduced LDL-cholesterol by 30% and Lp(a) by 39% in high 
risk patients on statin therapy224. The phase III Randomized Evaluation of the Effects of 
Anacetrapib Through Lipid-Modification (REVEAL) trial in patients with pre-existing 
atherosclerotic vascular disease who were already on an effective LDL-cholesterol lowering 
regimen (mean LDL-cholesterol at randomization of 1.6 mmol/L (61 mg/dL)) showed a 
statistically significant decrease in major coronary events of 9% (HR 0.91 95% CI 0.85-0.97) 
in the inervenion group compared to placebo 225,226. Unfortunately, patients with CKD and a 
serum creatinine level >200 μmol/L (>2.3 mg/dL) or with ESRD were excluded from this study. 
However, no benefit of anacetrapib was observed in patients with an eGFR <60 ml/min/1.73m2 
or macroalbuminuria, although the number of patients was small and there was no significant 
heterogeneity with respect to other groups.  
 
Interestingly, the beneficial effects of anacetrapib seem to be the result of lowering non-HDL-
cholesterol levels, rather than increasing HDL-cholesterol223. Anacetrapib is unlikely to 
become a licensed drug because the manufacturer has stopped development and a present will 
not be filing for approval. Clinical development of the CETP inhibitor obicetrapib was also 
halted in view of the REVEAL trial results, despite data from a phase II RCT showing that this 
agent increased HDL-cholesterol levels by >160% and decreased LDL-cholesterol levels by 
47%227. 
 
These results of clinical trials with CETP inhibitors are perhaps not surprising. Some have 
suggested that the rise in HDL-cholesterol levels that is caused by administration of these 
agents is not solely due to enhanced reverse cholesterol transport. [Au: Please reference this 
statement.] Instead this effect is caused by blockade of the exchange of the cholesterol cargoes 
of HDL particles with the triglyceride cargo of IDL particles. This process is essential to 
transform oxidation-prone, pro-inflammatory and atherogenic IDL particles and triglyceride-
rich LDL particles to cholesterol-ester rich LDL particles, which are removed from the 
circulation by liver LDL-receptors (Figure 1)228,229. 
 
[H2] Targeting lipoprotein(a) 
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Circulating levels of Lp(a) are fairly refractory to lifestyle and drug interventions, including 
statin therapy230. Only nicotinic acid, PCSK9 inhibitors and cetrapibs such as anacetrapib have 
been shown to lower Lp(a) levels by 15-25%, 15-30%, and 35-40%, respectively31,231. IONIS-
APO(a) (previously called ISIS 681257) is an antisense oligonucleotide targeting the Lp(a) 
gene that was show to be safe and to decrease plasma Lp(a) levels by up to 80% in a phase I 
RCT232. Phase II RCTs with IONIS-APO(a) and IONIS-APO(a)-I, a ligand conjugated 
antisense oligonucleotide variant, have shown reductions in plasma Lp(a) of up to 96% [Au: 
In which population?] 233. Currently no data are available on clinical outcomes using these 
agents. 
 
[H2] Inhibitors of VLDL production 
Inhibition of VLDL particle production decreases the levels of the downstream LDL particle31. 
Lomitapide inhibits microsomal triglyceride transfer protein (MTTP)234, which assembles 
lipids with ApoB to form lipoproteins and mipomersen is an antisense agent that inhibits the 
synthesis of ApoB235-237. However, both agents may cause liver steatosis and are currently only 
in use as adjunct therapy in homozygous familial hypercholesterolemia31,238-241. No data are 
available on cardiovascular outcomes with either lomitapide or mipomersen242,243. 
 
[H2] ApoC-III antisense oligonucleotide 
Increased levels of ApoC-III and the presence of ApoC-II in ApoB–conaining liposomes, 
ApoA-containing lipoproteins and Lp(a) are associated with increased atherogenic risk244,245. 
[Au: What is the mechanism of this increased risk?] An Apoprotein C-III gene antisense 
oligonucleotide, volanesorsen, has been shown to decreases serum triglyceride levels and [Au: 
the incidence of?] pancreatitis in patients with familial chylomicronemia syndrome245,246. 
Additional studies of volanesorsen are ongoing in patients with hypertriglyceridemia and other 
populations. [Au: Please reference this statement.]  
 
[H2] Targeting angiopoietin-like protein 3 
Angiopoietin-like proteins (ANGPTL) are important regulators of lipid metabolism247 and 
ANGPTL3 is an endogenous inhibitor of LPL. Loss of function mutations of ANGPTL3 are 
associated with decreased LDL-cholesterol and triglyceride concentrations247. In healthy 
volunteers, the anti-ANGPTL3 antibody evinacumab reduced triglyceride levels by up to 76% 
and LDL-cholesterol by up to 23%247 with similar reductions observed with the antisense 
oligonucleotide ANGPTL3-LRx, 63% and 33%, respectively
248. 
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[H2] HDL-peptide mimetics 
HDL-peptide mimetics are parenteral drugs tha mimic the structural and functional properties 
of HDL precursors and stimulate reverse cholesterol transport31. In a phase 2B RCT, the 
plasma-derived ApoAI peptide CSL112 increased ApoA-I levels and ex vivo cholesterol efflux 
in patients who had experienced myocardial infarction in the week before enrollment but did 
not modify [Au: the incidence of?] major atherosclerotic events (a secondary end point)249. A 
study of CSL112 in patients with CKD stage 3 is ongoing (NCT02742103) [Au: Please cite 
and include this trial in the reference list. If no data have been published a reference to 
the trial page at clinicaltrials.gov will be sufficient.].  
 
CER-001 consists of recombinant human ApoA-I complexed with phospholipids that mimic 
HDL precursors250. A phase 2 RCT failed to show any effect of CER-001 on plaque regression 
in [Au: 507?] patients with post-acute coronary syndrome251. However, a subsequent analysis 
of the trial data by a second core laboratory did demonstrate reductions in total atheroma 
volume [Au: in the intervention group compared wih the placebo group or compared to 
volume at enrollment?]252,253. A repeat imaging trial is currently comparing the efficacy of 
high dose CER-001 versus placebo [Au: in what population?]253. 
 
[H1] Implications for health economics 
In 2009, the healthcare costs associated with cardiovascular disease across the European 
Union was €106 billion, approximately 9% of the total health care outlay79. Most cost-
effectiveness studies of cardiovascular disease prevention combine research data and 
simulation models79,144,254-258 and estimates of cost-effectiveness can vary hugely depending 
on the assumptions made with regards to some basic parameters, especially the age and 
cardiovascular risk of the target population and the cost of the intervention79. Therefore, 
results for one condition or country will not necessarily be applicable to other situations. The 
incidence of serious adverse events can also have a major impact on cost-effectiveness144 as 
can the availability of generic drugs259. 
 
Despite the adverse effects discussed above, the cost-effectiveness of statin therapy [Au: for 
the prevention of cardiovascular events?] in the general population is well established and 
the benefits persist in the long-term. [Au: Please reference his statement.] Moreover, for each 
year statin therapy is prolonged larger absolute benefits accrue144. In paients with CKD the 
evidence [Au: for cost-effectiveness of statin therapy?] is limited. However, studies from the 
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US and UK suggest comparable cost-effectiveness of statins for prevention of cardiovascular 
events [Au: in the general population?] and in patients with CKD not on dialysis256,261.  
 
Given the increased cardiovascular risk that is associated with CKD, the mollified effect of 
LDL-cholesterol reduction on cardiovascular events in patients with reduced renal function and 
the increased intolerance of high-dose statins [Au: Do you mean increased incidence of 
adverse effects in patients with CKD? Please reference.] treatment with novel lipid-
modifying drugs might be an attractive option for physicians and their patients. Such a 
preference could be a matter of concern [Au: for healthcare providers?], especially given the 
currently excessive costs of these new agents 262-264. The issue of safety also needs to be 
addressed. The medical community as a whole, and the field of nephrology in particular, has 
previously fallen into the trap of extrapolating data from basic science, observational studies 
or clinical studies in other populations to justify treatments [Au: in patients with CKD?] that 
have eventually been shown to not be beneficial or even be damaging in later RCTs in this 
population 265-270. 
 
[Au: Paragraph moved from the end of this section to improve flow. OK?] As any 
investment in a new therapy reduces the resources that are available for other therapies278, 
lipid-modifying agents should be evaluated carefully for their health-economic impact as well 
as for their safety in patients with CKD12. In the past, patients with significant CKD [Au: 
Please clarify what you mean by “significant CKD”?] were routinely excluded from 
cardiovascular trials279. However, pressure should be put on regulatory and licensing 
authorities to demand the inclusion of patients with CKD in these trials in the future. Similar 
approaches together with several incentives have already improved the recruitment of 
women, children, elderly people and ethnic minorities into RCTs280-282. 
 
The importance of lifestyle modification, including adhering to a healthy diet, regular 
exercise, smoking cessation and maintaining a healthy weight is emphasized by many 
guidelines aimed at lowering cardiovascular risk in the general population, both before and 
after the use of lipid-lowering treatment79,184,271-274. However, such modifications remain an 
underexploited health-economic resource12. In Germany, societal costs from non-
communicable diseases including CKD might decrease by €168 (£149; $207) billion per year 
if the population improves their dietary intake [Au: Do you mean “reduces their dietary 
intake of salt, sugar and saturated fat”?] to the recommended levels275. The idea of 
imposing a ‘fat tax’ or ‘health’ is controversial but might lead to a modification of dietary 
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habits 276 and decrease societal costs of non-communicable diseases 277. In addition, the 
income raised by such a tax could be reinvested in health. Careful attention to health-
economic aspects should become an essential aspect of medical and political decision-
making, including regarding lipid-lowering in CKD 12. 
 
[H1] The KDIGO Clinical Practice Guideline 
The 2013 KDIGO Clinical Practice Guideline for Lipid Management1 has caused extensive 
[Au: Our journal style is to avoid use of “significantly” unless referring to statistical 
significance.] discussion and controversy 283-285. Similar to all KDIGO guidelines published 
to date, production of this guideline involved a thorough and rigorous process. Notably, the 
document makes recommendations for treatment but is not a rigid set of instructions. This 
point is especially important given that several of the recommendations were based on weak 
evidence. Although the summary recommendations can be interpreted as being very rigid, the 
guideline document puts these recommendations into context with plenty of room for 
personalization for individual patients. This context is especially important given that 
guidelines as a whole tend to be simplifications, which makes them easier to remember and 
implement but can result in the misclassification of individual patients286,287. In the 5 years 
since the publication of the KDIGO guideline, new clinical data has become available, novel 
therapies have emerged and other lipid management guidelines have been published. The 
KDIGO guideline deserves consideration and comment in the light of these developments 
(Table 3). 
 
[H2] Assessment of lipid status 
The KDIGO guideline recommends assessment of a lipid profile consisting of total cholesterol, 
LDL-cholesterol, HDL-cholesterol and triglycerides but does not recommend measurement of 
Lp(a), ApoB and other lipid markers1. As discussed above, emerging evidence suggests that 
these biomarkers might have utility in risk prediction and stratification in the general 
population and several subsequently published guidelines recommend their measurement79,184. 
However, their usefulness [Au: for risk prediction or for diagnosis?] in patients with CKD 
remains to be established. 
 
Perhaps most controversially 283,284, the KDIGO guideline does not recommend follow-up 
measurement of lipid levels for the majority of patients. The evidence level for this statement 
is “not-graded” and the recommendation is based on the lack of data on treatment escalation 
to achieve specific LDL-cholesterol targets, substantial within person variability in LDL-
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cholesterol measurements and the increased potential for medication toxicity in patients with 
CKD288-290. However, other reasons for follow-up measurements might exist, including 
monitoring or incentivizing adherence to treatment, which is known to be low in patients with 
CKD291, change in renal replacement modality or concerns about the presence of new 
secondary causes of dyslipidaemia1.  
 
Other guidelines do suggest target cholesterol reductions79,184. The reasons for this difference 
are complex. Only taking into account evidence from RCTs ignores the totality of the 
available evidence so restricts the potential to prevent cardiovascular disease. Systematic 
reviews have repeatedly confirmed a dose-dependent reduction in cardiovascular events with 
lowering of LDL-cholesterol levels; that is, the greater the reduction in LDL-cholesterol, the 
greater the reduction in cardiovascular risk143,145. The benefits of reducing LDL-cholesterol 
do not seem to be restricted to statin treatment292. In addition, no level of LDL-cholesterol 
below which further reduction is not associated with benefit or results in harmful effects has 
ever been defined. Furthermore, considerable variability exists in the reduction in LDL-
cholesterol levels that is achieved with therapy 293. These factors support a tailored 
individualized approach to treatment with the setting of goals [Au: Edit OK?] to assist 
doctor–patient communication and potentially enhance adherence. Such an approach is 
particularly relevant to patients who are considered to be at very high cardiovascular risk, 
such as those with advanced CKD or ESRD, those who have recently experienced an acute 
cardiovascular event and those with genetic disorders of cholesterol metabolism and 
significant hypercholesterolaemia in whom statins are indicted. 
 
[H2] Cholesterol-lowering treatment [Au: I have reordered the text in this section to 
improve flow.] 
The KDIGO guideline recommends that patients with CKD stages 3-5 (not on dialysis) aged 
≥50 years are treated with a statin or statin plus ezetimibe combination1. This 
recommendation is based on robust evidence and is consistent with other guidelines that do 
not recommend the use of risk assessment tools in this population. In adults with CKD stages 
3-5 aged 18-49 years, KIDIGO recommends treatment if they have known coronary artery 
disease, diabetes mellitus, had a previous ischaemic stroke or an estimated 10-year incidence 
of coronary death or non-fatal myocardial infarction greater than 10%. Although the evidence 
for this recommendation is fairly weak, it is consistent with most other current guidelines 
(Table 4).  
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In contrast to the KDIGO guidelines, some guidelines advocate the use of lifetime-estimated 
risk of cardiovascular disease, rather than 10-year risk, to inform treatment decisions294. [Au: 
Edit OK?] The rationale is that estimates of 10-year risk might offer false reassurance over 
the longer term, especially in young patients who have a high lifetime risk295. This point 
might be particularly relevant for young patients with CKD in whom cardiovascular 
morbidity and mortality increase with age and deteriorating renal function. [Au: Please 
reference this statement.]  
 
As statins and other cardioprotective drugs have become considerably less expensive and 
evidence of their long-term safety and efficacy has increased over time, considerable scope 
exists to extend their use beyond the traditional 10-year cardiovascular risk threshold. 
Furthermore, lipid levels change over time in response to certain treatments (such as 
immunosuppressive therapies), disease progression or remission and the development of 
malnutrition [Au: Is he development of malnutrition particularly relevant for patients 
with ESRD?]. Until concrete evidence exists regarding [Au: statin use or use of lipid-
lowering therapy in general?] in patients with CKD, decisions on treatment are likely to 
continue to be based on acceptability, cost-effectiveness and practicality. 
 
The KDIGO guideline also recommends treatment for patients with CKD stages 1-2 (eGFR 
>60 ml/min/1.73 m2) aged >50 years who have pathological albuminuria (urinary 
albumin:creatinine ratio >30 mg/g). This recommendation is based on observational studies 
given the absence of RCTs specifically targeting this population. Although such treatment 
might be reasonable given the increased cardiovascular risk of these patients, the application 
of risk calculators as for the general population could equally be justified and would perhaps 
be more prudent. A CKD-cardiovascular disease model, incorporating albuminuria, has been 
developed as a resource for evaluating the health outcomes and cost-effectiveness of 
interventions in CKD 296. However, this model is based on data from the SHARP trial and is 
only applicable to patients with CKD stage 3B or higher. 
 
The KDIGO guideline does not specify an upper age limit [Au: for lipid-lowering 
therapy?], whereas most guidelines recommend treating individuals aged >75 years only for 
secondary prevention. This difference is related to the lack of validated risk calculators for 
older individuals and their exclusion from many trials. Given the concerns regarding high-
intensity statin usage in patients with CKD because of their increased polypharmacy and 
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comorbidity, a reasonable approach might be to tailor treatment in elderly individuals based 
on their individual preferences.  
 
The KDIGO guideline focuses on cardiovascular risk to guide treatment and does not 
recommend treatment of any patient on the basis of a “high” cholesterol level per se. 
However, other guidelines such as the 2016 European Guidelines on cardiovascular risk 
prevention suggest lifestyle advice and possible drug treatment if LDL-cholesterol level is 
≥4.9 mmol/L (≥ 190 mg/dL) even if the estimated 10-year cardiovascular risk is less than 1%. 
[Au: Please reference this guideline.] Furthermore this guideline suggests that most patients 
with a 10-year cardiovascular risk of 5–10% would benefit from lipid lowering therapy if 
baseline LDL-cholesterol is 2.6–4 mmol/L (100–155 mg/dL). This conclusion is based on the 
strong, robust and graded association between LDL-cholesterol levels and cardiovascular 
risk; the results of observational studies and trials of lipid lowering therapies using 
angiographic and clinical end-points; and the results of meta-analyses demonstrating a dose-
dependent reduction of cardiovascular risk with LDL-cholesterol reduction 142-145,293. These 
differing recommendations are relevant to the treatment of young patients with CKD and of 
patients on dialysis with subsantial hypercholesterolaemia who would not receive lipid 
lowering therapy based on the KDIGO guidelines. In these populations, tailoring of treatment 
based on patient preferences should perhaps be considered. 
 
In patients receiving statins, KDIGO advises reducing the dose if eGFR is <60 ml/min/1.73 m2, 
based on the reduced renal excretion of some statins, the increased polypharmacy and 
comorbidity [Au: of patients with CKD] and the doses of statins used in trials in CKD. This 
recommendation essentially means that high intensity statin therapy should be avoided. As 
moderate dose statin therapy is known to produce a mean reduction in LDL-cholesterol of 30%, 
[Au: Please reference this statement.] a substantial proportion of treated patients will not 
experience a  reduction in LDL-cholesterol levels of this magnitude. This point is important in 
certain situations, including after an acute coronary syndrome. For example, the TNT trial 
found that a large group of patients with eGFRs of 45–59 ml/min/1.73 m2 (CKD stage 3a) 
gained significant benefit from high dose atorvastatin therapy in terms of reduction of excess 
cardiovascular events150. Furthermore, the prescribing information for atorvastatin states that 
no dose adjustment is required for patients with CKD, whereas dose reduction for rosuvastatin 
is only required if the GFR is <30 ml/min/1.73m2. Indeed, given that statins are now 
inexpensive (in stark contrast with the emerging lipid-lowering therapies) an argument could 
be made for adopting or studying an approach whereby stain-based regimens are chosen to 
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maximise the absolute reduction in LDL-cholesterol to achieve the largest treatment benefits 
in patients with CKD (rather than any target or goal-based approach). However, this approach 
is not necessarily without risk and may well need to be reserved for patients with high LDL-
cholesterol levels. In addition to the intended inhibition of cholesterol production, statins 
inhibit the synthesis of byproducts of alternative (ie ubiquinone and dolichols) and 
intermediary (eg farnesyl-pyrophosphate and geranylgeranyl-pyrophosphates) pathways of 
mevalonate metabolism,297,298 which have important functions including protein synthesis and 
transport, regulation of cell and tissue growth, mitochondrial function and gene transcription 
299,300. These unintended effects may result in serious adverse effects, including myopathy or 
rhabdomyolysis and hepatotoxicity, especially when statins are used at high doses in vulnerable 
patients with CKD or ESRD and low LDL-cholesterol levels297,300.  
 
The KDIGO guideline recommends that statins or combination therapy with a statin and 
ezetimibe should not be initiated in patients on dialysis 1. However, they suggest that patients 
who are already receiving such therapy at the time of dialysis initiation should not 
discontinue. This recommendation is based on the SHARP trial in which 2,141 patients with 
CKD progressed to needing dialysis during the study period but were analysed in the non-
dialysis group in which overall benefit was observed156. These two recommendations seem 
rather incongruous and somewhat difficult to reconcile with the remaining KDIGO guidance. 
They partly reflect the very limited RCT evidence available rather than the totality of 
evidence.  
 
One possible explanation for why a patient on dialysis might benefit from statin-based 
treatment only if they were receiving this therapy before dialysis initiation relates to the 
duration of treatment and/or exposure to risk. Although all RCTs of cholesterol-lowering 
therapies in patients on dialysis have been conducted over a period of around 5-years, the 
period of exposure to risk in the study participants is much longer with the atherosclerotic 
process having started years or decades earlier. As such, the 2016 Canadian Cardiovascular 
Society Guidelines for the Management of Dyslipidaemia274 suggest initiating treatment in 
paiens on dialysis if they are likely to eiher remain on dialysis for many years or receive a 
transplant. Indeed, this suggestion seems to align with the KDIGO recommendation of 
treating all adult kidney transplant recipients with a statin. It also appears to be particularly 
relevant for diabetic patients on dialysis with high LDL-cholesterol levels (>3.76 mmol/L; 
>145 mg/dL)155. 
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[H1] Conclusions 
Patients with all stages of CKD including those with ESRD on dialysis and kidney transplant 
recipients remain at high cardiovascular risk. Despite this risk, patients with CKD have 
repeatedly been shown to be less likely [Au: than patients without CKD?] to receive statin 
therapy for primary or secondary prevention of cardiovascular events301. In this context of 
under-treatment, the 2013 KDIGO guideline for lipid management provides pragmatic 
guidance for lipid-lowering treatment. However, some of the KDIGO recommendations, 
especially for situations with a poor evidence base, can be considered too restrictive when 
compared to other guidelines aimed at the general population [Au: Edit OK?].  
 
Starting lipid-lowering therapy, especially in patients with no previous cardiovascular event, 
can be a complex process. Shared decision making is especially important when the risks and 
costs of an intervention are immediate and the benefits are in the future. Two patients may 
choose different strategies and both are right based on their preferences. As a rule, clinicians 
should help to inform choices but avoid dictating treatments. Similarly, the role of guidelines 
is to inform choices but not to dictate them, especially in areas where the evidence is weak. 
 
Several novel therapies to manage dyslipidaemia are in clinical development. To be useful 
for patients with CKD, these agents must be safe, effective, available and of proven benefit in 
clinical trials in this population. Many of the novel treatments are bio-drugs [Au: biologics?] 
that are very expensive to produce. Thus, even if these agents are proven to be safe and 
effective, as well as being readily available, the high manufacturing costs may make them 
unaffordable so restrict their widespread use. The very real challenge for physicians 
managing patients with CKD and ESRD is to ensure that we get the evidence to support or 
refute the use of next generation lipid-lowering agents in this population without having to 
rely on extrapolation from studies in the general population. We must avoid, as has too often 
happened in the past, the widespread use of expensive and unproven treatments that later turn 
out to be unsafe or ineffective. The responsibility for this [Au: do you mean “for ensuring 
safety and efficacy”?] rests largely with manufacturers and regulatory authorities. However, 
as health-care professionals we too must push for, conduct and commit to large RCTs to 
answer these important questions. Importantly, all physicians looking after patients with 
CKD or ESRD must enroll [Au: those who are willing to participate?] into RCTs if we are 
to deliver the best possible care with the resources available. 
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Key points  
 An independent, graded inverse relationship exists between cardiovascular risk and 
estimated glomerular filtration rate; patients with end-stage renal disease (ESRD) are 
at extremely high risk of cardiovascular events 
 In chronic kidney disease (CKD) and ESRD, dysregulation of lipid metabolism 
results in increased levels of triglycerides and oxidised lipoproteins and reduced 
levels of high-density lipoprotein cholesterol; low-density lipoprotein cholesterol 
levels are usually normal 
 As eGFR declines, there is a trend towards smaller relative risk reductions for major 
vascular events with statin-based therapy with little evidence of benefit in patients on 
dialysis 
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 Deteriorating renal function results in a unique cardiovascular phenotype with an 
increasing proportion of cardiovascular deaths due to heart failure and arrhythmias, 
rather than due to atherosclerotic events 
 Several novel therapies are being developed to treat dyslipidaemias and their 
associated risks; most of these agents are biologics, which are very expensive to 
produce 
 Currently there is very little evidence to support the use of novel lipid-lowering agents 
in patients with CKD or ESRD; however a need exists for further studies of these 
therapies 
[Au: I suggest that we cut Box 1 as your Review is already very long with 8 display 
items and the box is not necessary to aid understanding of the article. If you feel 
strongly that the box should be included please shorten the text to fit our limit of 300 
words and cite it in the text. Alternatively the box could be included in supplementary 
information.] 
 
Figure 1. Derangements in lipoprotein metabolism in chronic kidney disease. [Au: 
Edited title ok?] In the endogenous pathway, the liver secretes triglyceride-rich VLDL 
particles that transport triglycerides to peripheral tissues. As triglycerides are hydrolysed by 
LPL, the VLDL particles decrease in size to become IDL particles and finally LDL particles, 
which retain considerable amounts of cholesterol. The LDL particles transport cholesterol to 
the liver and peripheral tissues and are cleared by the LDL receptor, as well as by other 
specific receptors and scavenger receptors. In the exogenous pathway, triglyceride-rich 
chylomicrons transport dietary lipids absorbed from the gut. Chylomicrons are catabolised by 
LPL, resulting in the generation of free fatty acids that are taken up by liver, muscle and 
adipose tissue. Chylomicrons rapidly diminish in size to become chylomicron remnants that 
are taken up by the liver via the LDL receptor. HDL particles have a key role in the process 
of reverse cholesterol transport, which transports cholesterol from peripheral cells [Au: such 
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as macrophages and endothelial cells?] to the liver. As renal function declines, a gradual 
quantitative shift towards a uraemic lipid profile occurs. [Au: Please provide some more 
detail of the changes that characterize this profile?]The lipid profile is also further 
modified by co-morbidities including diabetes mellitus and nephrotic syndrome. In parallel to 
the quantitative changes, major qualitative changes in the lipoprotein particles that render 
them more atherogenic also occur, including increased oxidation. ABCA1, ATP-binding 
cassette transporter A1; ABCG1, ATP-binding cassette transporter G1; ApoA-I, 
apolipoprotein A-I; ApoA-IV; CETP, cholesteryl ester transfer protein; IDL, intermediate-
density lipoprotein; LCAT, lecithin–cholesterol acyltransferase; LDL-R, LDL receptor; LPL, 
lipoprotein lipase; LRP; SR-B1, scavenger receptor B1; VLDL, very low-density lipoprotein. 
[Au: Please define c-LDL]  
 
Figure 2 Role of proprotein convertase subtilisin/kexin type 9 (PCSK9) in cholesterol 
transport. a | LDL particles bind to LDL-receptors (LDL-R) on the surface of cells to form a 
complex that is taken up by the cell. As pH decreases inside the endosome [Au:OK?], the 
LDL-receptor dissociates from this complex. LDL-cholesterol is incorporated into the cell 
and the LDL-receptor recycles to the cell surface. b | PCSK9 is an extracellular protein that 
binds directly to the LDL-receptor and induces its internalization and degradation. 
Therapeutic agents that target PCSK9 either reduce the synthesis of the protein or block its 
binding to the LDL-receptor. These agents prevent degradation of the LDL-receptor so 
preserve LDL-receptor recycling, which increases LDL-receptor density on the hepatocyte 
surface so enables more LDL-cholesterol to be removed from the circulation. LDL, low 
density lipoprotein; PCSK9, proprotein convertase subtilisin/kexin type 9; VLDL, very low 
density lipoprotein. 
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Figure 3 | Role of cholesteryl ester transfer protein (CETP) in cholesterol transport. 
HDL particles are initially cholesterol-free lipoproteins that are synthesized in hepatocytes 
and enterocytes. Extrahepatic tissues remove excess cholesterol by transferring it as free 
cholesterol to HDL particles. This free cholesterol is then either sent to the liver directly in a 
process dependent on hepatic scavenger receptor B1 (SR-B1) or indirectly via conversion 
into cholesteryl esters by LCAT. Cholesteryl esters are transported to the liver either by a 
direct but minor pathway that is dependent on SR-B1 or via an indirect major pathway that 
involves transfer to VLDL and LDL particles by CETP. Cholesterol ester is then taken up by 
the liver from these particles via the LDL receptor (LDL-R). Inhibition of CETP increases 
HDL-cholesterol levels and decreases the amount of cholesterol in atherogenic ApoB-
containing VLDL and LDL particles. CETP, Cholesteryl ester transfer protein; LCAT, 
lecithin-cholesterol acyltransferase; LDL-R, low density lipoprotein-receptor. 
 [Au: I suggest that we cut figure 4 as it is not original and it does not add value to your 
Review. The meta-analysis is cited and interested readers can refer to the original paper 
if they want more details on the results.] 
 
Table 1 | Lipid Profiles associated with CKD, dialysis and nephrotic syndrome. 
[Au: Ref 34 was published in 2007 so this data is quite old. Please update the table 
with recent data and references if possible. We will look into obtaining 
permissions to adapt the table but if we are not able to obtain these we will have 
to cut it from the Review.]  
Parameter CKD stage 1-5 Nephrotic Syndrome Haemodialysis Peritoneal dialysis 
Total cholesterol     
LDL-cholesterol     
HDL-cholesterol     
Non-HDL-cholesterol*     
Triglycerides     
Lp(a)     
 
Normal (), increased (), markedly increased (), and decreased () plasma levels 
compared with patients with normal renal function; increasing () plasma levels with 
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decreasing glomerular filtration rate. *Non-HDL-cholesterol includes cholesterol in low-
density lipoprotein, very low-density lipoprotein, intermediate-density lipoprotein and 
chylomicrons and their remnants. Adapted from Kwan CH et al 34  
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Table 2 |  Emerging lipid-modifying therapies [Au: I have reformatted this table to 
fit our journal style and page layout (portrait orientation). ATP citrate lyase 
inhibitors, acetylcoenzyme A carboxylase inhibitors and diacylglycerol 
acyltransferase 1 inhibitors do not seem to be discussed in the main text. Please 
check if these should be included/discussed.]  
Target Drug family Mechanism [Au: 
Please check if 
my edits are 
correct.]  
Individual 
drugs 
Status Results [Au: In this 
column when more 
than one drug is listed 
please specify which 
result is for which 
drug.]  
Ref(s) 
PCSK9  PCSK9 
inhibitors 
Increase the 
clearance of LDL 
particles 
Alirocumab, 
evolocumab, 
bococizumab. 
[Au: Which 
drugs?] available 
for FH 
Development of 
Bococizumab halted 
[Au: Which drug(s)?] 
reduced the risk of major 
cardiovascular events in 
high-risk individuals and 
in patients with FH 
204, 
210,214 
PCSK9 siRNA Increase the 
clearance of LDL 
particles 
Inclisiran  Phase II RCT 
completed 
Lowered LDL-cholesterol 
levels [Au: in which 
population?]  
216 
ATP citrate lyase ATP citrate 
lyase inhibitor 
Reduces the 
synthesis of LDL 
particles 
Bempedoic 
acid  
Phase II RCT 
completed 
Lowered LDL-cholesterol 
and C-reactive protein 
levels [Au: in which 
population]  
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CETP CETP inhibitors Inhibit the 
exchange of 
cholesteryl esters 
and triglycerides 
between HDL and 
TG-rich 
lipoproteins 
Torcetrapib  
Evaccetrapib 
Dalcetrapib  
Anacetrapib  
Obicetrapib. 
Phase III RCT [Au: 
of which drugs?] 
completed 
Clinical 
development [Au: 
of which drug?] 
halted  
[Au: Which drugs?] 
Increased HDL and 
decreased LDL 
cholesterol levels [Au: in 
which population]  
Lower atherosclerotic 
events with Anacetrapib 
[Au: in which 
population?]  
121,222,12
3,225,227 
ApoA-I ApoA-I mimic 
peptides  
[Au: Increase or 
decrease?] the 
cholesterol efflux 
capacity of HDL 
particles 
CSL112 
CER-001  
Phase II RCTs 
completed 
Phase III RCT 
announced for 
CSL112 
Conflicting results on 
atheroma regression 
[Au: With which drug? 
In patients with post-
acute coronary 
syndrome?]  
249,252 
Lp(a) [Au: 
changed from 
Apo(a) OK?]  
Lp(a) antisense 
oligonucleotide 
[Au: Inhibition 
of?] Lp(a) 
synthesis 
IONIS-APO(a)  Phase II RCTs 
completed 
Lowers plasma Lp(a) 
>90% [Au: in which 
population] 
233 
MTTP  MTTP inhibitor Inhibition of VLDL 
particle production 
Lomitapide  Available for FH  >50% reduction in LDL-
cholesterol [Au: in which 
population] 
234 
ApoB  ApoB antisense 
oligonucleotide 
Inhibition of ApoB 
synthesis 
Mipomersen  Available for FH  >50% reduction in LDL-
cholesterol [Au: in which 
population] 
235 
ANGPTL3 Anti-ANGPTL3 
antibody 
[Au: inhibits?] 
VLDL particle 
secretion 
Evinacumab Phase II RCT 
completed 
Phase III RCT 
ongoing 
Lower triglycerides (76%) 
and LDL-cholesterol 
(23%) [Au: in which 
population] 
247 
ANGPTL3 
antisense 
oligonucleotide 
[Au: inhibits?] 
VLDL particle 
secretion 
ANGPTL3-LRx Phase I/II RCT 
completed 
Lower triglycerides (63%) 
and LDL-cholesterol 
(33%) [Au: in which 
population] 
248 
Acetylcoenzyme A 
carboxylase  
Acetylcoenzyme 
A carboxylase 
inhibitor 
Enhances the 
clearance of VLDL 
particles 
Gemcabene  Phase II RCT 
completed 
Phase III RCT 
planned 
Lower LDL-cholesterol, 
and C-reactive protein 
levels [Au: in which 
population?]  
303 
ApoC-III  ApoC-III 
antisense 
oligonucleotide 
Triglyceride-rich 
ApoC-III-
lipoproteins [Au: 
What is the 
effect on these 
Volanesorsen  Phase III RCT 
completed 
Filed for Federal 
Drug Administration 
approval 
Lowers triglyceride levels 
in patients with familial 
chylomicronemia 
[Au:OK?]  
245 
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lipoproteins – 
what specifically 
is targeted?]  
Diacylglycerol 
acyltransferase 1  
Diacylglycerol 
acyltransferase 
1 inhibitor 
Reduces 
triglyceride 
synthesis [Au: in 
chylomicrons?] 
Pradigastat  Phase III RCT 
terminated 
Lower triglycerides (70%) 
[Au: in which 
population]. 
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ANGPTL3, angiopoietin-like 3; ApoA-I, apolipoprotein A-I; ApoB, apolipoprotein B; ApoC-
III, apolipoprotein C-III; CETP, cholesteryl ester transfer protein; CKD, chronic kidney 
disease; FH, familial hypercholesterolaemia; HDL, high density lipoprotein; LDL, low 
density lipoprotein; LDL-Lp (a), lipoprotein (a); MTTP, microsomal triglyceride transfer 
protein; PCSK9, proprotein convertase subtilisin-kexin type 9; RCT, randomised 
controlled trial; sCr, serum creatinine; siRNA, small interfering RNA; VLDL, very low 
density lipoprotein. 
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Table 3 | Suggested areas for revision of the KDIGO Clinical Practice Guideline for 
lipid management in CKD1. [Au: Edited title OK? We have a limit of 98 characters 
including spaces.]  
 
KDIGO Recommendation Potential revision 
Assessment of lipid status 
In adults with newly identified CKD (including those treated with 
chronic dialysis or kidney transplantation), we recommend evaluation 
with a lipid profile (total cholesterol, LDL cholesterol, HDL 
cholesterol, triglycerides). (1C) 
Consideration might be given to other emerging 
markers of dyslipidaemia (e.g. lipoprotein(a), 
Apolipoprotein B), although these should mostly be 
reserved for research studies 
In adults with CKD (including those treated with chronic dialysis or 
kidney transplantation), follow-up measurement of lipid levels is not 
required for the majority of patients. (Not Graded) 
Consider follow-up measurement in certain 
circumstances, for example in response to changes in 
clinical status and/or medications, in situations where 
intensive lipid lowering is potentially beneficial and 
to reinforce adherence 
Pharmacological cholesterol-lowering treatment 
In adults aged ≥50 years with eGFR<60 ml/min/1.73 m2 but not treated 
with chronic dialysis or kidney transplantation (GFR categories G3a-
G5), we recommend treatment with a statin or statin/ezetimibe 
combination.  
 
In adults aged ≥50 years with CKD and GFR>60 ml/min/1.73 m2 (GFR 
categories G1-G2) we recommend treatment with a statin.  
 
In adults aged 18–49 years with CKD but not treated with chronic 
dialysis or kidney transplantation, we suggest statin treatment in people 
with one or more of the following:  
 known coronary disease (myocardial infarction or coronary 
revascularization)  
 diabetes mellitus  
 prior ischemic stroke  
 estimated 10-year incidence of coronary death or non-fatal 
myocardial infarction >10%  
 
In adults with dialysis-dependent CKD, we suggest that statins or 
statin/ezetimibe combination not be initiated  
 
In patients already receiving statins or statin/ezetimibe combination at 
the time of dialysis initiation, we suggest that these agents be continued 
 
In adult kidney transplant recipients, we suggest treatment with a statin 
Consideration needs to be given to patients with 
progressive CKD, especially if high levels of 
proteinuria are present 
 
Potential consideration also needs to be given to 
patients with high estimated life-time risk likely to 
progress to dialysis and transplantation. 
 
In individuals with known coronary disease, 
secondary prevention recommendations may apply, 
including LDL-cholesterol targets 
 
Consider decision to be individualised if patient is 
expected to have a long renal career, receive a kidney 
transplant or has high LDL cholesterol levels 
Triglyceride-lowering treatment  
In adults with CKD (including those treated with chronic dialysis or 
kidney transplantation) and hypertriglyceridemia, we suggest that 
therapeutic lifestyle changes be advised 
[Au: NA?]  
 
Abbreviations: CKD, chronic kidney disease; GFR, glomerular filtration rate; HDL-
cholesterol, high density lipoprotein cholesterol; LDL-cholesterol, low density 
lipoprotein cholesterol; [Au: NA, not applicable.] 
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Table 4 | Summary of guidelines for lipid-modification [Au: Should this be lipid-
lowering therapy?] therapy for the management of dyspipidaemia  
 
Society (year) Recommendations Assessment of risk 
for primary 
prevention 
Patients with CKD or ESRD [Au: I’ve 
merged this coulumn with the other 
notes column OK?]  
Ref 
KDIGO (2013) 
[Au: Please 
complete to enable 
easy comparisons]  
   1 
American College of 
Cardiology/American 
Heart Association 
(2013) 
Different statin intensity 
depending on 10-year ACSVD 
risk and presence of other risk 
factors 
10-year risk of ACSVD 
using the pooled 
cohorts equation 
No recommendation for patients on 
dialysis or those with severe heart failure 
271 
Joint British Societies 
(2014) 
Target non-HDL-cholesterol 
<2.5mmol/L and LDL-
cholesterol <1.8 mmol/L 
JBS-3 risk calculator, 
to assess 10-year and 
life-time CVD risk 
No risk estimation required for CKD 
stages 3-5 
No mention of patients on dialysis except 
an indirect reference to KDIGO guidelines 
294 
Cardiovascular 
disease: risk 
assessment and 
reduction, including 
lipid modification 
(2014; updated 2016) 
Low, medium, high intensity 
statin treatment depending on 
risk for primary prevention 
High intensity (atorvastatin 
80 mg) for secondary 
prevention. 
10-year CVD event 
risk using the QRISK2 
assessment tool. 
Risk assessment not required if GFR <60 
ml/min/1.73 m2 or albuminuria (level not 
defined) 
Offer atorvastatin 20 mg to patients with 
CKD for the primary or secondary 
prevention of CVD 
Aim for >40% reduction in non-HDL-
cholesterol and consider increasing dose 
if this target is not achieved. 
No reference to patients on dialysis or 
transplant recipients 
272 
European 
Atherosclerosis 
Society/European 
Society of Cardiology 
(2016) 
Target LDL-cholesterol <1.8 
mmol/L in very high risk, <2.6 
in high risk and <3.0 in low to 
intermediate risk patients 
10-year risk of first 
fatal cardiovascular 
event using SCORE 
system 
Patients with CKD are considered to be at 
high or very high cardiovascular risk 
Have broadly accepted KDIGO 
recommendations 
79 
Sixth Taskforce 
European Society of 
Cardiology and other 
societies (2016) 
Target LDL-cholesterol <1.8 
mmol/L in very high risk, <2.6 
in high risk and <3.0 in low to 
intermediate risk patients 
10-year risk of first 
fatal CV event using 
SCORE system 
Patients with CKD are considered to be at 
high or very high cardiovascular risk 
Have broadly accepted KDIGO 
recommendations  
273 
US Preventative 
Services Task Force 
(2016) 
All offered low-to moderate 
dose statins 
Primary prevention 
recommended for adults aged 
<75 years only [Au:OK?] 
10-year risk of CVD 
using the ACC/AHA 
pooled cohorts 
equation 
No recommendations provided [Au:OK?]  305,3
06 
Canadian 
Cardiovascular 
Society (2016) 
Target > 50% LDL-cholesterol 
reduction 
10-year Framingham 
Heart Study Risk 
Score modified for 
family history or CV 
age using 
Cardiovascular Life 
Expectancy Model 
(CLEM)  
Risk assessment not required if GFR <60 
ml/min/1.73 m2or ACR > 3.0 mg/mmol 
Suggest not initiating lipid lowering 
treatment in patients on dialysis 
Treatment might be desireable in younger 
individuals and in those who might 
become eligible for kidney 
Otherwise broadly similar to KDIGO. 
274 
American Society of 
Endocrinologists 
2017) 
Treatment goals for LDL-
cholesterol should be 
personalized to levels of risk 
low <130 mg/dL, moderate & 
high <100 mg/dL, very high 
<70 mg/dL, extreme < 55 
mg/dL 
10-year risk of a 
coronary event using 
either Framingham 
Risk Assessment Tool, 
MESA, Reynolds Risk 
Score, UKPDS risk 
engine 
Patients with CKD stages 4-5 are 
classified as high, very high or extreme 
risk depending on the presence of other 
risk factors 
184 
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Conventional to SI units conversion: LDL-cholesterol: mg/dl to mmol/L conversion 
factor 0.0259. ACR: mg/g to mg/mmol conversion factor 0.113 
